AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in …

"People living with active non-radiographic axial spondyloarthritis suffer from chronic inflammatory back pain and limited physical function that can be …
Source: back pain